You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

 

Online download statistics by month:

Online download statistics by month: April 2022 to April 2023

AbstractFullPdf
Apr 202211001134482
May 20229671006326
Jun 2022841872271
Jul 2022851862164
Aug 2022731746153
Sep 2022756764175
Oct 2022767776174
Nov 2022669677168
Dec 2022577577117
Jan 202355055282
Feb 2023523524102
Mar 2023551553128
Apr 2023529532119
Total941295752461